**7.6 Brentuximab vedotin**

*Advances in Hematologic Malignancies*

tions, *diarrhea, cough and dizziness.*

roidism, myelodysplasia, acute leukemia.

improvements in self-rated overall QOL [58].

infusion is 9 or 18 mcg/kg/day given for 8 courses every 3 weeks.

comes with complete remission [CR] and an ORR of 67% [49].

**7.3 Denileukin diftitox**

**7.4 Ofatumumab**

**7.5 Obinutuzumab**

*7.2.2 Tositumomab iodine I 131*

which include lymphoma refractory to rituximab.

FDA in February 2002 approved 90Y ibritumomab tiuxetan for treatment of refractory and relapsing indolent follicular lymphoma or transformed lymphoma

The toxicity of ibritumomab tiuxetan is primarily hematologic, which is both transient and reversible. The common side effects, nausea, vomiting, drug interac-

Is a CD20 radiotherapeutic targets for treatment of lymphoma patients with positive CD20 especially cases of indolent low grade lymphoma, transformed lymphoma, refractory and relapsed lymphoma and lymphoma refractory to rituximab. The therapeutic administration protocol contain two separate products of tositumomab and iodine I131 tositumomab which will be given in two different steps include dosimetric dose and therapeutic dose separated by 10 days interval.

A relapsed, refractory, or transformed indolent low grade lymphoma overall response (OR) rates have ranged from approximately 60–80% and CR rates have ranged from about 20–40% and a median duration of response of 2 years [57]. Tositumomab toxicities include severe and prolonged thrombocytopenia and neutropenia as well as increase risk of developing other diseases include hypothy-

In June 2003, Tositumomab approved by FDA for treatment of CD20+ follicular lymphoma, that was relapsed following chemotherapy or lymphomas refractory to rituximab.

Denileukin diftitox (Ontak) is a fusion protein (interleukin 2 and diphtheria toxin) approved by FDA in October 16, 2008, for use as an antineoplastic agent to treat pretreated patients with CD25 positive cutaneous T cell lymphomas that express IL-2 receptors. A phase III clinical trial, had good response and significant

Denileukin diftitox is available in solution in 2 mL single use vials of 150 μg/mL (300 mcg in 2 mL) under the brand name Ontak. The typical dose of intravenous

Epratuzumab is an antihuman CD22 IgG1 antibody that targets CD22 antigen, found on the surface of B-lymphocytes antigen, CD22 [59, 60]. This drug, either in single administration or in combination with rituximab, created promising out-

In August 2009, ofatumumab was approved as a high-affinity IgG1 mAb that binds to a membrane-proximal epitope of the CD20 molecule of the B cell with potential anti-neoplastic activity triggering and exhibited greater induction of complementdependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells over expressing CD20 when compared with rituximab [61].

Is a unique monoclonal antibody, designed to attach to CD20 antigen expressed on the surface of pre-B- and mature B-lymphocytes of malignant lymphoma and for maintenance treatment of patients previously untreated low grade lymphoma especially follicular type resulted in significant free survival. The post-translational

**128**

An anti-CD30 antibody-drug conjugate and demonstrated significant clinical activity in patients with CD30<sup>+</sup> malignancies, including Reed Sternberg cells in classical HL and anaplastic large cell lymphoma (ALCL) (**Tables 4** and **5**).
